News and Events >

Wright Medical Group Completes Acquisition of BioMimetic

BioMimetic Therapeutics, Inc. Initiates Enrollment in Augment™ Chronic Tendinopathy Clinical Trial

BioMimetic Therapeutics Submits Augment® Bone Graft PMA Amendment to FDA

Timothy Daniels, MD Presents Results from Augment™ Injectable Bone Graft Clinical Trial

Newly Published Augment Bone Graft Products Compare Favorably with Autologous Bone Graft

BioMimetic Therapeutics Announces Augment Rotator Cuff Data

BioMimetic Therapeutics Announces Augment Rotator Cuff Data

BioMimetic Therapeutics' Augment™ Bone Graft Receives Positive Recommendation from FDA Advisory Panel

What do you mean by Reject Ordinary?

Reject ordinary is a state of mind and call to action. This is not about us, as much as it is about the surgeon, our customer. Every surgeon is extraordinary—gifted with the ability to treat injuries, correct deformities and address the challenges of aging. We, too, embrace this call to excellence and choose to develop products that are innovative, backed by rigorous science and represented by people who are knowledgeable about the products they sell.

Read more about our advances here, so you too, can reject ordinary.



 


RECENT ANNOUNCEMENTS


BioMimetic Therapeutics, Inc. Initiates Enrollment in Augment™ Chronic Tendinopathy Clinical Trial
January 3 2013

Wright Medical Group, Inc. and BioMimetic Therapeutics, Inc. Enter Into Agreement to Combine Businesses
November 19 2012

BioMimetic Therapeutics, Inc. Reports Third Quarter 2012 Financial Results
November 5 2012